Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 3Triple Negative Breast Neoplasms 2Melanoma 2Ganglioneuroblastoma 2Unilateral Breast Neoplasms 1Resectable Esophageal Cancer 1Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Locally Advanced Pancreatic Adenocarcinoma 1Leukemia, Plasma Cell 1Inflammatory Breast Neoplasms 1Gliosarcoma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Temozolomide 8sargramostim 2pembrolizumab 2Radiotherapy 2Radiation 2veliparib 1selinexor 1montanide ISA 51 1lonafarnib 1Vorinostat 1Sucrose 1Sonication 1Sodium Chloride 1Serotonin Antagonists 1Salts 1Photons 1Perfusion Magnetic Resonance Imaging 1Olanzapine 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1Loperamide 1Lomustine 1Irinotecan 1Granulocyte-Macrophage Colony-Stimulating Factor 1Drug Therapy 1Cyclophosphamide 1Colony-Stimulating Factors 1Carboplatin 1CLR1404 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Gliosarcoma × Colony-Stimulating Factors × Clear all
NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Roswell Park Cancer Institute

Phase 2 Active not recruiting
66 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡